A coalition of anti-marijuana groups and a cannabis-focused biopharmaceutical corporation filed a new brief on Monday with the U.S. Court of Appeals for the District of Columbia Circuit. The filing asks the appeals court to reconsider a May ruling by Judge Trevor N. McFadden that dismissed their challenge to a Centers for Medicare & Medicaid Services program.
The program covers up to $500 worth of hemp-derived products each year for eligible Medicare patients.
The plaintiffs include Smart Approaches to Marijuana (SAM), Cannabis Industry Victims Educating Litigators (CIVEL), the Hillsborough County Anti-Drug Alliance and MMJ International Holdings and its subsidiaries. The program focuses largely on CBD but also allows a certain amount of THC in products. The initiative is known as the hemp-focused Substance Access Beneficiary Engagement Incentive (BEI).
The immediate issue focuses on standing. McFadden found that MMJ lacks standing because it has not yet brought a product to the market and is “not a direct and current competitor with anyone selling hemp to Medicare beneficiaries.”
“In short, MMJ has no product on the Medicare-beneficiary market and no sense of when it may,” he said. The new brief argues that the company is “not a speculative future entrant” in the market.
The brief says MMJ has “invested over $10 million across more than eight years, obtained Orphan Drug Designation, submitted IND applications for two cannabinoid therapeutics, and holds a DEA Schedule I analytical-laboratory registration.” It states that standing as a competitor “does not require an approved product.”
The brief also argues that the government cannot credibly label MMJ a speculative future entrant when the government’s own delay of nearly eight years on a bulk-manufacturing application at DEA caused the company’s pre-approval status. “The government should not profit from its own obstruction,” it says.
Beyond standing, the brief argues the Medicare hemp program is “both procedurally defective in its adoption and materially harmful to market competitors, healthcare providers, and elderly Americans.” McFadden had ruled that each plaintiff “claims an injury too abstract or too remote to open the courtroom doors.”
A New Day in Texas Sarah Todd, director of the Texas Cannabis Policy Center, said she felt optimism for an…
Amendments Follow Five-Year Review The Provincial Government has introduced amendments to the Cannabis Control Act in Newfoundland and Labrador. The…
Rejected Applicant Takes Chula Vista to Court Laura Wilkinson Sinton, a small business owner from Coronado, applied to open a…
Trulieve Plans Dispensary At Former Ozona Grill Site A medical cannabis dispensary is set to take over the former Ozona…
TribeTokes Tops THC-Free Sleep Gummy Rankings A product review has named the TribeTokes CBD + CBN Sleep Gummy the best…
A Pioneer Preserves a Movement's Origins Fifty years after her late husband became the first American in modern times to…